Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed and/or Refractory CD33+ AML”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 12 of 0 results

Early research (Phase 1)WithdrawnNCT05248685
What this trial is testing

Optimized Dual CD33/CLL1 CAR T Cells in Subjects With Refractory or Relapsed Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia
Beijing Boren Hospital
Very early researchUnknownNCT03795779
What this trial is testing

CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies

Who this might be right for
Hematologic MalignancyAcute Myeloid LeukemiaMyelodysplastic Syndromes+2 more
iCell Gene Therapeutics 20
Early research (Phase 1)Active Not RecruitingNCT03927261
What this trial is testing

PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS

Who this might be right for
Acute Myeloid LeukemiaMyelodysplastic Syndromes
Precigen, Inc 88
Early research (Phase 1)Looking for participantsNCT05105152
What this trial is testing

PLAT-08: A Study Of SC-DARIC33 CAR T Cells In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML

Who this might be right for
Acute Myeloid LeukemiaAcute Myeloid Leukemia RefractoryAcute Myeloid Leukemia, in Relapse
Seattle Children's Hospital 18
Early research (Phase 1)Study completedNCT03915379
What this trial is testing

JNJ-67571244 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Who this might be right for
Leukemia, Myeloid, AcuteMyelodysplastic Syndromes
Janssen Research & Development, LLC 68
Not applicableNo Longer AvailableNCT02312037
What this trial is testing

Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy

Who this might be right for
CD33 Positive Acute Myelogenous Leukemia
Pfizer
Early research (Phase 1)Ended earlyNCT03126864
What this trial is testing

Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia

Who this might be right for
Hematopoietic/Lymphoid CancerAcute Myeloid Leukemia
M.D. Anderson Cancer Center 11
Testing effectiveness (Phase 2)Looking for participantsNCT07523555
What this trial is testing

Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies

Who this might be right for
Relapsed/Refractory B-cell Acute Lymphoblastic LeukemiaRelapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLLRelapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia+4 more
Beijing Biotech 96
Early research (Phase 1)Study completedNCT03144245
What this trial is testing

Study of AMV564 in Patients With AML

Who this might be right for
Acute Myeloid Leukemia
Amphivena Therapeutics, Inc. 53
Large-scale testing (Phase 3)UnknownNCT00006045
What this trial is testing

Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia

Who this might be right for
Leukemia
Facet Biotech
Early research (Phase 1)Study completedNCT04070768
What this trial is testing

Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113

Who this might be right for
Acute Myeloid Leukemia
John Quigley 18
Early research (Phase 1)UnknownNCT05445765
What this trial is testing

Anti-CD33 CAR-T Cells for the Treatment of Relapsed/Refractory CD33+ Acute Myeloid Leukemia

Who this might be right for
Relapsed and/or Refractory Acute Myeloid LeukemiaHigh Risk Hematologic Malignancies
iCell Gene Therapeutics 10